Lung Cancer Clinical Trials

Find Lung Cancer Clinical Trials Near You

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Signed written informed consent.

• Male or female, aged ≥ 18 and \< 85 years.

• Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer.

• Tumor tissue and blood samples obtainable at all protocol-specified time-points.

• No pure ground-glass nodule on imaging.

• Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy.

Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Kezhong Chen
mdkzchen@163.com
+86-010-88325983
Backup
Yue He
hy771999@163.com
+86-010-88325983
Time Frame
Start Date: 2025-05-08
Estimated Completion Date: 2027-10-31
Participants
Target number of participants: 100
Treatments
High-risk group
High-risk recurrence groups identified by the multi-omics model
Low-risk group
Low-risk recurrence groups identified by the multi-omics model
Related Therapeutic Areas
Sponsors
Leads: Peking University People's Hospital

This content was sourced from clinicaltrials.gov